2.1. Setting and Participants

JL John Charles A. Lacson
SD Scarlet H. Doyle
LQ Lu Qian
JR Jocelyn Del Rio
SF Stephanie M. Forgas
SV Stella Valavanis
RC Rodrigo Carvajal
GG Guillermo Gonzalez-Calderon
YK Youngchul Kim
RR Richard G. Roetzheim
SS Steven K. Sutton
SV Susan T. Vadaparampil
PK Peter A. Kanetsky
request Request a Protocol
ask Ask a question
Favorite

Participants were recruited from two university-associated primary care clinics in Florida between September 2015 and September 2018. Participant data were captured and managed throughout the study using an in-house HIPAA-compliant web-based database management system. Inclusion criteria were: (1) non-Hispanic, (2) white, (3) at least 18 years of age, and (4) fluent in English. Exclusion criteria included: (1) report of a full-body skin examination within the past year and (2) personal history of melanoma.

Participants were required to have brown/black natural hair color at 18 years old and at least three of the following criteria: (1) mild to no freckling at summer’s end; (2) brown or black natural eye color; (3) mild to no burning after exposure to a first strong summer sun; and (4) medium to dark tan after prolonged sun exposure. This phenotypic eligibility structure assured that participants had only limited phenotypic risk characteristics; individuals with Fitzpatrick skin type I [16], the most sun-sensitive skin type, were systematically considered ineligible. This structure did result in the inclusion of individuals who reported one risk phenotype, e.g., painful or severe burning after exposure to the sun for the first time during summer, as long as it was reported in the absence of other phenotypic risk factors. Starting in December 2016, eye color was removed from the eligibility criteria to increase the number of potentially eligible participants. Patients with subsequent clinic appointments previously ineligible because of eye color and had at least two of the three remaining criteria were re-approached.

This protocol was registered in April 2018 on clinicaltrials.gov (NCT03509467).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A